Previous work has evaluated the effect of CB2 (JWH-015, JWH-133) agonists on breast cancer models (Hanlon et al., 2016; Elbaz et al., 2017; Zhang et al., 2018) and were able to reduce the size of breast cancer tumors. The gene discussed is CNR2; the disease is breast carcinoma.